Lung Cancer Clinical Trials & Research at Providence Medical Group

The two main types of lung cancer are non-small cell lung cancer and small cell lung cancer. The types are based on the way the cells look under a microscope. Non-small cell lung cancer is much more common than small cell lung cancer. Tobacco smoking is the most common cause of lung cancer.

Providence Medical Group is currently enrolling patients for the following lung cancer clinical trials:

A study for patients with non small cell lung cancer with c-Met Exon 14 skip mutations and c-Met dysregulation advanced solid tumors

Treatment agent: APL-101 oral capsule
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: https://classic.clinicaltrials.gov/ct2/show/NCT03175224
Sponsor: Apollomics Inc.
Location: Providence Cancer Center, Santa Rosa, CA

A study for patients with Stage II-IIIB EFGR+ non small cell lung cancer who have had a resection with or without adjuvant chemotherapy: AZ D5162C000048 (TARGET)

Treatment agent: Osimertnib
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

A study for patients with stage II-IIIA resectable EGFR+ non small cell lung cancer before surgery

Treatment agent: Osimertnib as monotherapy or in combination with chemotherapy vs standard of care alone
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

A study for patients with unresectable Stage IIIB non small cell lung cancer after chemotherapy and radiation: AZ D9075C00001- PACIFIC 8

Treatment agent: Durvalumab
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative (Alliance A082002)

Treatment agent: Radiotherapy + Immunotherapy (+/- Chemotherapy)
Physician: Michael N. Corradetti
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: https://clinicaltrials.gov/study/NCT04929041
Sponsor: National Cancer Institute (NCI) / Alliance for Clinical Trials in Oncology
Location: Providence Queen of the Valley Medical Center, Napa, CA

A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) HLX10-020-SCLC302

Treatment agent: Serplulimab (HLX10) vs Placebo + Chemotherapy + Radiotherapy
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: https://www.clinicaltrials.gov/study/NCT05353257
Sponsor: Shanghai Henlius Biotech
Location: Providence Cancer Center, Santa Rosa, CA

A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as High or Intermediate Risk by a 14-Gene Prognostic Assay

Treatment agent: Adjuvant Chemotherapy + Radiographic surveillance + 14-Gene Prognostic Assay
Physician: Ian Anderson, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: https://clinicaltrials.gov/study/NCT01817192
Sponsor: Razor Genomics
Location: Providence Cancer Center, Santa Rosa, CA

Study for participants with unresectable Pleural Mesothelioma (eVOLVE-Meso)

Treatment agent: Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab
Physician: Dr Ian Anderson
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: Study Details | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma

Treatment agent: VMD-928 (oral CNS-penetrant) + selective inhibitor of TrkA
Physician: Ian Anderson, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: Study Details | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | ClinicalTrials.gov
Sponsor: VM Oncology, LLC
Location: Providence Cancer Center, Santa Rosa, CA

A Phase 1b/2, Multicenter, OpenLabel Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (EMD Serono MS202329-0010 PROCEADE)

Treatment agent: Anti-CEACAM5 Antibody-Drug Conjugate M9140
Physician: Ian Anderson, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study Details | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | ClinicalTrials.gov
Sponsor: EMD Serono Research & Development Institute, Inc
Location: Providence Cancer Center, Santa Rosa, CA

Bluestar study to test a new drug in participants with advanced or metastatic ovarian, endometrial or HER2-breast cancer

Treatment agent: AZD8205- a B7-H4 targeted antibody drug conjugate (ADC)
Physician: Ian Anderson, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors

Treatment agent: INBRX-106 (Hexavalent OX40 Agonist)
Physician: Ian Anderson, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study Details | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | ClinicalTrials.gov
Sponsor: Inhibrx Biosciences, Inc
Location: Providence Cancer Center, Santa Rosa, CA

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum- Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS)

Treatment agent: JNJ-61186372 (amivantamab) and JNJ-73841937 (lazertinib)
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: Study Details | A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | ClinicalTrials.gov
Sponsor: Janssen Research & Development, LLC
Location: Providence Cancer Center, Santa Rosa, CA

A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer

Treatment agent: Ivonescimab
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: Study Details | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | ClinicalTrials.gov
Sponsor: Summit Therapeutics
Location: Providence Cancer Center, Santa Rosa, CA

Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 overexpressing Nonsmall Cell Lung Cancer

Treatment agent: Trastuzumab Deruxtecan
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Treatment agent: Rilvegostomig (AZD2936) - D702FC00001
Physician: Ian Anderson, MD
Study Coordinator: Tracy Foster // tracy.foster@stjoe.org // 707-521-3830
Study Resources: Study Details | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA